The Rainbow Seed Fund
c/o CLIK Rutherford Appleton Laboratory Harwell Science And Innovation Campus Chilton, Didcot, Oxfordshire, OX11 0QX, United Kingdom
Overview
The UK Innovation & Science Seed Fund is backed by the Department for Business, Energy and Industrial Strategy and the Fund’s partners are 9 publicly funded research bodies, including STFC, BBSRC, NERC and Dstl. The Fund is independently managed by venture capital specialist Midven. They help build companies from great science developed in laboratories, science and technology campuses and synthetic biology. They hold investments in some of the UK’s most innovative companies, in areas as diverse as novel antibiotics, research into Alzheimer’s disease, “green” chemicals and airport security.
- Total investments
- 2
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Biotechnology
- Financial Services
- Venture Capital
Investment portfolio
- Nemesis Bioscience
Led · Seed · May 2017
Nemesis Bioscience is a Cambridge and Cardiff–based developer advancing Bacterial Cybergenetics technologies to resurrect antimicrobial therapies compromised by increasing microbial resistance. Its product suite includes Nemesis Symbiotics, aimed at reversing antibiotic resistance, and Transmids for clinical, veterinary and industrial delivery. The company’s Cybergenetics technologies use modified, multiplexed programmable RNA-guided endonucleases; the first has been shown to inactivate resistance to beta-lactam antibiotics by targeting eight families of beta-lactamases, including ESBLs, carbapenemases and metallo-beta-lactamases. Nemesis sees large opportunities in the antibiotic, wound care and veterinary medicine markets. Founded in March 2014, the company intends to use the funds from its recent seed raise to validate its suite of technologies. It raised over £700k in the seed round led by The Rainbow Seed Fund with Finance Wales and Dr Mark McCamish as co-investors.
- Cytox
Participated · Equity · Apr 2014
Cytox is a UK diagnostics company developing blood-based assays and prognostic biomarkers tied to mTOR pathway dysfunction for early risk assessment and prediction of Alzheimer’s and other dementias. The company has exclusive rights to cell cycle–related biomarker discoveries by its scientific founder and is advancing those findings through clinical evaluation. Cytox is running two clinical programmes in the European Union and North America and recently began an extensive evaluation programme for its mTOR pathway biomarker technology. It operates state-of-the-art laboratory facilities in Manchester and has a partnership with US-based Selah Genomics to support testing and development. Management says the new funding will extend its clinical research programme, help secure potential utility claims, and enable partnerships with academia and pharmaceutical companies to support drug-development efforts. Financially, Cytox has raised multiple rounds totaling in excess of £5M in the past 15 months.
Team
No current team members are available.